Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients

A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05933239

Acronym

MAGMA

Enrollment

Registered

2023-07-06

Start date

2023-03-30

Completion date

2027-04-01

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

PET/CT, MMR-PET/CT, Macrophage PET/CT, CD206

Brief summary

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

Interventions

DRUG68GaNOTA-Anti-MMR-VHH2

Injection of the radiopharmaceutical and PET/CT imaging

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who have given informed consent * Patients at least 18 years old * Patient with local, locally advanced or metastatic disease of non-small cell lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions * Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the

Exclusion criteria

at time of second inclusion.

Design outcomes

Primary

Measure	Time frame	Description
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in a NSCLC lesion before surgery with the immunohistological MMR-staining of the excised lesion.	Resection of lesion up to 21 days after PET/CT	PET/CT and immunohistochemistry will be assessed using a (semi-)quantitative scale.

Countries

Belgium

Contacts

CONTACTUZ Brussel

nucg.clinicaltrials@uzbrussel.be+32 2 477 6013

PRINCIPAL_INVESTIGATORTony Lahoutte, MD, PhD

Universitair Ziekenhuis Brussel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026